AstraZeneca (NASDAQ:AZN) announced positive high-level results from its EMERALD-3 Phase III trial, demonstrating that a novel combination of immunotherapies and targeted treatment significantly improved outcomes for patients with the most common form of liver cancer.
The trial found that a cocktail of Imfinzi (durvalumab), Imjudo (tremelimumab-actl), and lenvatinib—administered alongside transarterial chemoembolization (TACE)—met the primary endpoint of progression-free survival (PFS).
The regimen showed a statistically significant and clinically meaningful improvement over TACE alone in patients with unresectable hepatocellular carcinoma (HCC) who are eligible for embolization.
HCC represents a major global health challenge, with more than 200,000 patients expected to be eligible for embolization in 2026.
While TACE is the current standard of care—blocking blood supply to tumors while delivering chemotherapy—most patients see their disease progress or recur within six to ten months.
The EMERALD-3 data suggests that moving systemic immunotherapy earlier into the treatment cycle can break this cycle of recurrence.
The study utilized the "STRIDE" regimen (Single Tremelimumab-actl Regular Interval Durvalumab) as the backbone of the investigational therapy.
At an interim analysis, the combination also showed a positive trend toward improving overall survival (OS), a key secondary endpoint that the trial will continue to monitor.
Meanwhile, the safety profiles for the medications remained consistent with previous clinical experience, with no new safety signals reported.
AstraZeneca confirmed it is preparing to present the full data set at an upcoming medical meeting and has initiated discussions with global regulatory authorities to explore potential filing pathways.